全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Primary Signet Ring Cell Carcinoma of the Lung with Cerebellar Metastasis Showing Full Response to Cisplatin and Docetaxel Therapy

DOI: 10.1155/2014/968723

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction. Primary signet ring cell carcinoma (SRCC) of the lung is a very rare disease. We describe a new case of primary SRCC of the lung with cerebellar metastasis, which responded well to the therapeutic approach with cisplatin and docetaxel. Case Report. A 41-year-old female patient (nonsmoker) was consulted to our oncology outpatient clinic after cerebellar metastasectomy. The histopathological diagnosis was SRCC metastasis. The primary tumor was unknown. The PET-CT imaging showed a hypermetabolic mass in the right middle lobe of the lung and hypermetabolic mediastinal lymph node stations. Oesophagogastroduodenoscopy and colonoscopy showed no evidence of gastrointestinal system tumor. The clinical diagnosis of primary SRCC of the lung was made and the administration of six rounds of cisplatin and docetaxel treatment was planned. After the chemotherapy the PET-CT scan to evaluate the therapy response showed full metabolic regression of the primary tumor and the mediastinal lymph nodes. There was no evidence of new metastasis. Conclusion. Primary SRCC of the lung is a very rare disease with poor prognosis. There are not many cases in literature and no standardized chemotherapy protocols. Cisplatin and docetaxel may be a good treatment option. 1. Introduction Primary SRCC of the lung is a very rare disease. First described by Kish et al. in 1989, it is reported that incidence of primary SRCC of the lung varies from 0.14% to 1.9% of all lung cancers [1]. The largest series was taken by Tsuta et al. in which 39 of 2640 surgically resected primary lung carcinomas showed SRCC components. Mean age of the patients was 54.6 years, male to female ratio was 1.16?:?1.00, and 26 patients (66.7%) were smokers. The size of the SRCC component of the tumor positively correlated with the aggressiveness of the tumor and poor outcome. The 5-year survival was 28% [2]. 2. Case A 41-years-old female patient (nonsmoker) was consulted to our oncology outpatient clinic by the neurosurgery clinic after a cerebellar metastasectomy. The preop CT scan showed a right cerebellar hypodense lesion with the dimension of 5 × 5?cm (Figure 1). Figure 1: The preop CT scan showed a right cerebellar hypodens lesion. The histopathological examination of the metastasectomy material showed SRCC metastasis with positive immunostaining for CEA, CK 7, and TTF-1. The immunostaining with CK 20, ER, COX2, CK 14, CDX2, and MUC2 was negative. The histopathological morphology was shown Figures 2(a), 2(b), and 2(c). Figure 2: (a) Malign epithelial infiltration in the cerebellum with signet-ring

References

[1]  J. K. Kish, J. Y. Ro, A. G. Ayala, and M. J. McMurtrey, “Primary mucinous adenocarcinoma of the lung with signet-ring cells: a histochemical comparison with signet-ring cell carcinomas of other sites,” Human Pathology, vol. 20, no. 11, pp. 1097–1102, 1989.
[2]  K. Tsuta, G. Ishii, K. Yoh et al., “Primary lung carcinoma with signet-ring cell carcinoma components: clinicopathological analysis of 39 cases,” American Journal of Surgical Pathology, vol. 28, no. 7, pp. 868–874, 2004.
[3]  S. H. Merchant, M. B. Amin, P. Tamboli et al., “Primary signet-ring cell carcinoma of lung: immunohistochemical study and comparison with non-pulmonary signet-ring cell carcinomas,” American Journal of Surgical Pathology, vol. 25, no. 12, pp. 1515–1519, 2001.
[4]  J. Ye, J. J. Findeis-Hosey, Q. Yang et al., “Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung,” Applied Immunohistochemistry and Molecular Morphology, vol. 19, no. 4, pp. 313–317, 2011.
[5]  N. Fatima, C. Cohen, D. Lawson, and M. T. Siddiqui, “TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks,” Cancer Cytopathology, vol. 119, no. 2, pp. 127–133, 2011.
[6]  H. Hayashi, H. Kitamura, Y. Nakatani, Y. Inayama, T. Ito, and H. Kitamura, “Primary signet-ring cell carcinoma of the lung: histochemical and immunohistochemical characterization,” Human Pathology, vol. 30, no. 4, pp. 378–383, 1999.
[7]  B. Xu, N. Thong, D. Tan, and T. Khoury, “Expression of thyroid transcription factor-1 in colorectal carcinoma,” Applied Immunohistochemistry and Molecular Morphology, vol. 18, no. 3, pp. 244–249, 2010.
[8]  W. Dubinski, N. B. Leighl, M. -S. Tsao, and D. M. Hwang, “Ancillary testing in lung cancer diagnosis,” Pulmonary Medicine, vol. 2012, Article ID 249082, 8 pages, 2012.
[9]  S. J. Rodig, M. Mino-Kenudson, and S. Dacic, “Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population,” Clinical Cancer Research, vol. 15, pp. 5216–5223, 2009.
[10]  A. T. Shaw, B. Y. Yeap, B. J. Salomon et al., “Effect of Crizotinib on overall survival in patients with advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized, phase 3 study,” The Lancet Oncology, vol. 12, pp. 735–742.
[11]  S.-H. I. Ou, A. Ziogas, and J. A. Zell, “Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung,” Journal of Thoracic Oncology, vol. 5, no. 4, pp. 420–427, 2010.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133